Imaging based Body Composition Profiling and Outcomes After Oncologic Liver Surgery

Overview

Journal Front Oncol

Specialty Oncology

Date 2022 Dec 26

PMID 36568174

Authors

Lorenzo Bernardi

Raffaello Roesel

Filippo Vagelli

Pietro Majno-Hurst

Alessandra Cristaudi

Affiliations

Soon will be listed here.

Abstract

Body composition profiling is gaining attention as a pre-operative factor that can play a role in predicting the short- and long- term outcomes of patients undergoing oncologic liver surgery. Existing evidence is mostly limited to retrospective and single-institution series and in many of these studies, the evaluation of body composition is based on parameters which are derived from CT-scan imaging. Among body composition phenotypes, sarcopenia is the most well studied but this is only one of the possible profiles which can impact the outcomes of oncologic hepatic surgery. Interest has recently grown in studying the effect of sarcopenic obesity, central obesity, or visceral fat amount, myosteatosis, and bone mineral density on -such patients. The objective of this review is to summarize the current evidence on whether imaging-based parameters of body composition have an impact on the outcome of patients undergoing liver surgery for each of the most frequent indications for liver resection in clinical practice: hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), and colorectal liver metastases (CRLM).

Citing Articles

Beyond body mass index: Body composition profiling for perioperative risk stratification in intrahepatic cholangiocarcinoma patients.

Kolck J, Hosse C, Beetz N, Auer T, Marth A, Segger L Cancer Rep (Hoboken). 2024; 7(9):e2070.

PMID: 39324689 PMC: 11425665. DOI: 10.1002/cnr2.2070.

The Effects of Sarcopenia on Overall Survival and Postoperative Complications of Patients Undergoing Hepatic Resection for Primary or Metastatic Liver Cancer: A Systematic Review and Meta-Analysis.

Giakoustidis A, Papakonstantinou M, Chatzikomnitsa P, Gkaitatzi A, Bangeas P, Loufopoulos P J Clin Med. 2024; 13(13).

PMID: 38999435 PMC: 11242440. DOI: 10.3390/jcm13133869.

Prognostic utility of body composition parameters based on computed tomography analysis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors.

Park J, Jo J, Youk J, Kim M, Yoon S, Keam B Insights Imaging. 2023; 14(1):182.

PMID: 37880430 PMC: 10600077. DOI: 10.1186/s13244-023-01532-4.

Value of sarcopenia in the resection of colorectal liver metastases-a systematic review and meta-analysis.

Wagner D, Wienerroither V, Scherrer M, Thalhammer M, Faschinger F, Lederer A Front Oncol. 2023; 13:1241561.

PMID: 37841447 PMC: 10569723. DOI: 10.3389/fonc.2023.1241561.

References

Okuno M, Goumard C, Kopetz S, Vega E, Joechle K, Mizuno T . Loss of muscle mass during preoperative chemotherapy as a prognosticator for poor survival in patients with colorectal liver metastases. Surgery. 2018; 165(2):329-336. DOI: 10.1016/j.surg.2018.07.031. View

Xu L, Jing Y, Zhao C, Zhang Q, Zhao X, Yang J . Preoperative computed tomography-assessed skeletal muscle index is a novel prognostic factor in patients with hepatocellular carcinoma following hepatectomy: a meta-analysis. J Gastrointest Oncol. 2020; 11(5):1040-1053. PMC: 7657831. DOI: 10.21037/jgo-20-122. View

Itoh S, Shirabe K, Matsumoto Y, Yoshiya S, Muto J, Harimoto N . Effect of body composition on outcomes after hepatic resection for hepatocellular carcinoma. Ann Surg Oncol. 2014; 21(9):3063-8. DOI: 10.1245/s10434-014-3686-6. View

Meister F, Lurje G, Verhoeven S, Wiltberger G, Heij L, Liu W . The Role of Sarcopenia and Myosteatosis in Short- and Long-Term Outcomes Following Curative-Intent Surgery for Hepatocellular Carcinoma in a European Cohort. Cancers (Basel). 2022; 14(3). PMC: 8833751. DOI: 10.3390/cancers14030720. View

Enomoto H, Ueno Y, Hiasa Y, Nishikawa H, Hige S, Takikawa Y . The transition in the etiologies of hepatocellular carcinoma-complicated liver cirrhosis in a nationwide survey of Japan. J Gastroenterol. 2020; 56(2):158-167. PMC: 7862502. DOI: 10.1007/s00535-020-01748-x. View

Miyachi Y, Kaido T, Yao S, Shirai H, Kobayashi A, Hamaguchi Y . Bone Mineral Density as a Risk Factor for Patients Undergoing Surgery for Hepatocellular Carcinoma. World J Surg. 2018; 43(3):920-928. DOI: 10.1007/s00268-018-4861-x. View

Jang H, Choi G, Hwang S, Jang E, Kim J, Ahn J . Sarcopenia and visceral adiposity predict poor overall survival in hepatocellular carcinoma patients after curative hepatic resection. Transl Cancer Res. 2022; 10(2):854-866. PMC: 8799077. DOI: 10.21037/tcr-20-2974. View

Voron T, Tselikas L, Pietrasz D, Pigneur F, Laurent A, Compagnon P . Sarcopenia Impacts on Short- and Long-term Results of Hepatectomy for Hepatocellular Carcinoma. Ann Surg. 2014; 261(6):1173-83. DOI: 10.1097/SLA.0000000000000743. View

Miljkovic I, Vella C, Allison M . Computed Tomography-Derived Myosteatosis and Metabolic Disorders. Diabetes Metab J. 2021; 45(4):482-491. PMC: 8369205. DOI: 10.4093/dmj.2020.0277. View

10.

Kamachi S, Mizuta T, Otsuka T, Nakashita S, Ide Y, Miyoshi A . Sarcopenia is a risk factor for the recurrence of hepatocellular carcinoma after curative treatment. Hepatol Res. 2015; 46(2):201-8. DOI: 10.1111/hepr.12562. View

11.

Takagi K, Yagi T, Yoshida R, Shinoura S, Umeda Y, Nobuoka D . Sarcopenia and American Society of Anesthesiologists Physical Status in the Assessment of Outcomes of Hepatocellular Carcinoma Patients Undergoing Hepatectomy. Acta Med Okayama. 2016; 70(5):363-370. DOI: 10.18926/AMO/54594. View

12.

Higashi T, Hayashi H, Taki K, Sakamoto K, Kuroki H, Nitta H . Sarcopenia, but not visceral fat amount, is a risk factor of postoperative complications after major hepatectomy. Int J Clin Oncol. 2015; 21(2):310-319. DOI: 10.1007/s10147-015-0898-0. View

13.

Kobayashi A, Kaido T, Hamaguchi Y, Okumura S, Shirai H, Kamo N . Impact of Visceral Adiposity as Well as Sarcopenic Factors on Outcomes in Patients Undergoing Liver Resection for Colorectal Liver Metastases. World J Surg. 2017; 42(4):1180-1191. DOI: 10.1007/s00268-017-4255-5. View

14.

van Dijk D, Krill M, Farshidfar F, Li T, Rensen S, Olde Damink S . Host phenotype is associated with reduced survival independent of tumour biology in patients with colorectal liver metastases. J Cachexia Sarcopenia Muscle. 2018; 10(1):123-130. PMC: 6438330. DOI: 10.1002/jcsm.12358. View

15.

van Dijk D, Zhao J, Kemter K, Baracos V, Dejong C, Rensen S . Ectopic fat in liver and skeletal muscle is associated with shorter overall survival in patients with colorectal liver metastases. J Cachexia Sarcopenia Muscle. 2021; 12(4):983-992. PMC: 8350209. DOI: 10.1002/jcsm.12723. View

16.

Huang D, Singal A, Kono Y, Tan D, El-Serag H, Loomba R . Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer. Cell Metab. 2022; 34(7):969-977.e2. PMC: 9762323. DOI: 10.1016/j.cmet.2022.05.003. View

17.

Levolger S, Van Vledder M, Muslem R, Koek M, Niessen W, de Man R . Sarcopenia impairs survival in patients with potentially curable hepatocellular carcinoma. J Surg Oncol. 2015; 112(2):208-13. DOI: 10.1002/jso.23976. View

18.

Kroh A, Uschner D, Lodewick T, Eickhoff R, Schoning W, Ulmer F . Impact of body composition on survival and morbidity after liver resection in hepatocellular carcinoma patients. Hepatobiliary Pancreat Dis Int. 2018; 18(1):28-37. DOI: 10.1016/j.hbpd.2018.07.008. View

19.

Ross R, Neeland I, Yamashita S, Shai I, Seidell J, Magni P . Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity. Nat Rev Endocrinol. 2020; 16(3):177-189. PMC: 7027970. DOI: 10.1038/s41574-019-0310-7. View

20.

Fujiwara N, Nakagawa H, Kudo Y, Tateishi R, Taguri M, Watadani T . Sarcopenia, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma. J Hepatol. 2015; 63(1):131-40. DOI: 10.1016/j.jhep.2015.02.031. View